Krystina Browning, APRN
Nurse Practitioner · Danville, KYNPI 1598239287
Payments from drug & device makers
Across 439 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$950
- GSK$738
- Jazz Pharmaceuticals Inc.$714
- Takeda Pharmaceuticals U.S.A., Inc.$607
- AstraZeneca$554
- Boehringer Ingelheim$546
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,256100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 96 | $950 |
| GSK | 47 | $738 |
| Jazz Pharmaceuticals Inc. | 44 | $714 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $607 |
| AstraZeneca | 31 | $554 |
| Boehringer Ingelheim | 34 | $546 |
| Regeneron Healthcare Solutions, Inc. | 18 | $415 |
| Harmony Biosciences LLC | 18 | $350 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $330 |
| Actelion Pharmaceuticals US, Inc. | 7 | $254 |
| Johnson & Johnson | 12 | $219 |
| Verona Pharma, Inc. | 8 | $166 |
| Sanofi | 8 | $163 |
| QOL Medical, LLC | 6 | $147 |
| AbbVie | 7 | $136 |
| Amgen | 6 | $128 |
| Madrigal Pharmaceuticals | 3 | $93 |
| Nestle Healthcare Nutrition Inc. | 4 | $79 |
| Axsome Therapeutics, Inc. | 4 | $76 |
| Mylan Specialty L.p. | 3 | $69 |
| Lilly USA, LLC | 4 | $68 |
| Gilead | 5 | $67 |
| Merck | 3 | $65 |
| Intercept Pharmaceuticals, Inc. | 4 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Viatris Specialty LLC | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| Boston Scientific | 1 | $22 |
| Organogenesis Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Insmed, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,267 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 379 | $344,148 |
| Dupixent PenDupilumab | 26 | $113,892 |
| Spiriva RespimatTiotropium Bromide | 115 | $92,783 |
| Fasenra PenBenralizumab | 13 | $73,068 |
| Dupixent SyringeDupilumab | 17 | $64,004 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $44,322 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $43,259 |
| SymbicortBudesonide/Formoterol Fumarate | 128 | $37,564 |
| Spiriva HandihalerTiotropium Bromide | 41 | $35,807 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $24,846 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 705 | $22,481 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $18,697 |
| DuleraMometasone/Formoterol | 25 | $14,327 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $10,766 |
| Ventolin HfaAlbuterol Sulfate | 110 | $7,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $738 | $412,253486 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $546 | $122,246145 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $554 | $87,826187 claims |
| MerckDulera | $65 | $14,32725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Danville
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.